The long-anticipated gene therapy is now expected to be administered within the coming weeks. Families are advised that the precise schedule for the necessary treatment will be communicated in the near future. This therapeutic intervention addresses Duchenne muscular dystrophy (DMD), a severe and rare hereditary condition.
DMD is characterized by the body’s inability to produce sufficient levels of the protein dystrophin. This deficiency leads to progressive and gradual deterioration of the body’s muscles. Individuals diagnosed with the disorder typically lose the ability to walk around the age of twelve.
Over time, the disease’s impact extends beyond the limbs, affecting the muscles responsible for respiration, the hands, and the heart. The specific therapy in question, Elevidys, is a gene therapy developed in the United States. While current data indicates that this treatment does not cure DMD, it is expected to significantly slow the rate of the disease’s progression.
For patients like Jaka, access to this therapy represents a crucial development in managing the challenging symptoms associated with the condition. The imminent availability of the treatment is anticipated to provide a critical management tool. Receiving this therapy marks a significant milestone in care for DMD patients.
The medical team will ensure that Jaka and her family are fully informed regarding the protocols and the expected efficacy of the gene therapy as it is received.
Topics: #jaka #received #treatment
